This is not the most recent version of the article. View current version (13 NOV 2014)

Diagnostic Test Accuracy Protocol

PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer

  1. Mia Schmidt-Hansen1,*,
  2. David R Baldwin2,
  3. Elise Collins1,
  4. Javier Zamora3,
  5. Víctor Abraira3

Editorial Group: Cochrane Lung Cancer Group

Published Online: 7 DEC 2011

DOI: 10.1002/14651858.CD009519


How to Cite

Schmidt-Hansen M, Baldwin DR, Collins E, Zamora J, Abraira V. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD009519. DOI: 10.1002/14651858.CD009519.

Author Information

  1. 1

    National Collaborating Centre for Cancer, Cardiff, UK

  2. 2

    Nottingham University Hospitals, City Campus, Adult Cystic Fibrosis Unit, Nottingham, UK

  3. 3

    (b) CIBER Epidemiologia y Salud Publica (CIBERESP), (a) Unidad de Bioestadística, Hospital Ramón y Cajal, Madrid, Spain

*Mia Schmidt-Hansen, National Collaborating Centre for Cancer, 2nd Floor, Park House, Greyfriars Road., Cardiff, CF10 3AF, UK. Mia.Schmidt-Hansen@wales.nhs.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 7 DEC 2011

SEARCH

This is not the most recent version of the article. View current version (13 NOV 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To examine the accuracy of integrated PET-CT for mediastinal staging of patients with suspected or confirmed NSCLC which is potentially suitable for treatment with curative intent.   

To assess potential sources of heterogeneity including study design (e.g. retrospective/prospective, consecutive/random series), patient populations (number and characteristics, e.g. T- and N-stage, significant nodes on prior CT, country), different cut-off values for test positivity (malignancy), differences in PET-CT image acquisition and/or scanning equipment and potential differences in reference standard (mediastinoscopy/pathological or surgical staging).

See 'Secondary objectives'.